Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02807714 · ClinicalTrials.gov registry record
Role of Podocan and Wnt Pathway Regulatory Molecules in Coronary Artery Disease
A clinical trial of Coronary Artery Disease, sponsored by Jennifer Victory, RN, CCRC.
- Completed
- Registry status
- 571
- Enrollment target
- 1
- Study location
NCT02807714: Completed study of Coronary Artery Disease, sponsored by Jennifer Victory, RN, CCRC.
NCT02807714 is a study of Coronary Artery Disease that has completed, run by Jennifer Victory, RN, CCRC. The registered enrollment target is 571 participants, below the 1,284-participant average among 219 other Coronary Artery Disease trials with a reported enrollment target (56% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02807714, a study of Coronary Artery Disease, has completed, sponsored by Jennifer Victory, RN, CCRC.
- COMPLETED
- Registry status
- 571 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to find an association between a protein named Podocan and WNT pathway regulatory molecules in patients with different forms of Coronary Artery Disease (Acute Coronary syndrome, Stable Angina and Coronary Artery Restenosis). It has been found in experimental studies that this protein is regulating smooth muscle cell function and hence may be influencing the progression of Coronary Artery Disease (CAD). We are testing to see if the same regulatory function exists in human subjects. Studying patient's blood will possibly enable to identify an association between Podocan and CAD. This may help to better prevent and treat CAD with improved understanding of the mechanism of the disease. No drugs or other therapeutic interventions will be used for the purpose of the research study. Only blood samples will be collected in the cardiac catheterization lab. As a part of this study participants will be followed for repeat events or repeat cardiac catheterization over a period of 24 months.
Primary Outcome
Prior to catheterization, a peripheral blood sample will be obtained via an IV access line previously placed for the catheterization procedure. Blood samples will be frozen and stored in a -80°C freezer in the Research Institute.
Conditions Studied
Study Locations (1)
New York
- Bassett Healthcare Network - Cooperstown
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 571 participants |
| Start Date | 2016-06 |
| Est. Completion | 2020-12 |
What the finished NCT02807714 record still lists
NCT02807714 is an observational study that tracks outcomes without assigning an intervention. The registered 571 participants enrollment target is mid-sized for trials with a published cap, below the 1,284-participant average among 219 other Coronary Artery Disease trials with a reported enrollment target (56% lower).
The record links to 1 condition, with Coronary Artery Disease appearing as the primary indexed condition, and to 0 interventions.
NCT02807714 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT02807714 about?
NCT02807714 is a clinical study titled "Role of Podocan and Wnt Pathway Regulatory Molecules in Coronary Artery Disease". The purpose of this study is to find an association between a protein named Podocan and WNT pathway regulatory molecules in patients with different forms of Coronary Artery Disease (Acute Coronary syndrome, Stable Angina and Coronary Artery Restenosis). It has been found in experimental studies that...
What is the current status of trial NCT02807714?
This trial is currently completed. The enrollment target is 571 participants. The study started on 2016-06. Estimated completion is 2020-12.
What conditions does trial NCT02807714 study?
This clinical trial studies the following conditions: Coronary Artery Disease.
Who is sponsoring clinical trial NCT02807714?
This trial is sponsored by Jennifer Victory, RN, CCRC, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02807714 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Coronary Artery Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02807714's enrollment target sits among peer trials
571 72nd of 219 higher than 148 of 219 other Coronary Artery Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Coronary Artery Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
MCNAIR Study: coMparative effeCtiveness of iN-person and teleheAlth cardIac Rehabilitation
RECRUITING · NA
-
MagicTouch for Treatment of In-Stent Restenosis in Coronary Artery Lesions
RECRUITING · NA
-
PET/CT* vs. Cardiac CT for Detecting Coronary Atherosclerotic Disease [*PET: Positron Emission Tomography; CT: Computed Tomography]
RECRUITING · NA
-
Factors Affect Outcomes in Cardiovascular Surgery
RECRUITING
-
Polygenic Risk-based Detection of Subclinical Coronary Atherosclerosis and Change in Cardiovascular Health
RECRUITING · NA
-
Impact of Disclosing Coronary Artery Disease Polygenic Risk Score on Cardiovascular Health
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04410796 · 571 participants · Phase 2
Osimertinib Alone or With Chemotherapy for EGFR-Mutant Lung Cancers
- NCT05131022 · 572 participants · Phase 1
A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
- NCT06346392 · 572 participants · Phase 3
AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2
- NCT06615050 · 572 participants · Phase 3
A Study of Tacrolimus/Methotrexate/Ruxolitinib Versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in Non-Myeloablative/Reduced Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transplantation (BMT CTN 2203)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia